Loading
Life sciences · Journal article
Georgetown Medical Review · October 23, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background Polyendocrine metabolic ovarian syndrome (PMOS) is a common endocrine disorder affecting 5% to 15% of reproductive-aged individuals and is frequently accompanied by hyperinsulinemia and obesity. These metabolic disturbances contribute to gallbladder dysmotility and increased cholesterol synthesis, elevating the risk of cholelithiasis, cholecystitis, and cholangitis. Metformin is widely used to manage dyslipidemia, type 2 diabetes mellitus, and obesity in patients with PMOS, but emerging therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) may offer additional benefit. Methods This study used the TriNetX network to compare the incidence of gallbladder disease between patients with PMOS treated with metformin and those treated with GLP-1 RAs. After 1:1 propensity score matching on age, type 2 diabetes mellitus, obesity, body mass index, and lipid-lowering therapy, two cohorts of 53,258 patients were analyzed. Results Glucagon-like peptide-1 RAs were associated with a lower incidence of cholelithiasis and cholecystitis than metformin, whereas cholangitis rates were similar. Conclusion These findings suggest that GLP-1 RAs may confer a protective effect through weight reduction and improved insulin sensitivity. Further study is warranted to confirm the effect of GLP-1 RAs on cholelithiasis and cholecystitis.